324 related articles for article (PubMed ID: 19002789)
1. Topoisomerase I inhibitors and drug resistance.
Parchment RE; Pessina A
Cytotechnology; 1998 Sep; 27(1-3):149-64. PubMed ID: 19002789
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase targeting drugs: mechanisms of action and perspectives.
Malonne H; Atassi G
Anticancer Drugs; 1997 Oct; 8(9):811-22. PubMed ID: 9402307
[TBL] [Abstract][Full Text] [Related]
3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
4. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
5. DNA-topoisomerase inhibitors.
D'Incalci M
Curr Opin Oncol; 1993 Nov; 5(6):1023-8. PubMed ID: 8305535
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase I in multiple drug resistance.
Pessina A
Cytotechnology; 1993; 12(1-3):127-35. PubMed ID: 7764454
[TBL] [Abstract][Full Text] [Related]
7. High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors.
Pessina A; Raimondi A; Cerri A; Piccirillo M; Neri MG; Croera C; Foti P; Berti E
Cell Prolif; 2001 Aug; 34(4):243-52. PubMed ID: 11529882
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.
Chikamori K; Grozav AG; Kozuki T; Grabowski D; Ganapathi R; Ganapathi MK
Curr Cancer Drug Targets; 2010 Nov; 10(7):758-71. PubMed ID: 20578986
[TBL] [Abstract][Full Text] [Related]
9. Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs.
Mann CA; Carvajal Moreno JJ; Lu Y; Dellos-Nolan S; Wozniak DJ; Yalowich JC; Mitton-Fry MJ
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0048223. PubMed ID: 37724886
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
11. DNA repair functions that control sensitivity to topoisomerase-targeting drugs.
Malik M; Nitiss JL
Eukaryot Cell; 2004 Feb; 3(1):82-90. PubMed ID: 14871939
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners.
Long BH; Stringfellow DA
Adv Enzyme Regul; 1988; 27():223-56. PubMed ID: 2854948
[TBL] [Abstract][Full Text] [Related]
13. Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents.
Yakkala PA; Penumallu NR; Shafi S; Kamal A
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895927
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells.
Allen GC; Lubas S; Wax MK; Devore RF
Otolaryngol Head Neck Surg; 1996 Jun; 114(6):785-92. PubMed ID: 8643303
[TBL] [Abstract][Full Text] [Related]
15. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
Snyder RD
Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
[TBL] [Abstract][Full Text] [Related]
16. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Boland MP; Fitzgerald KA; O'Neill LA
J Biol Chem; 2000 Aug; 275(33):25231-8. PubMed ID: 10940316
[TBL] [Abstract][Full Text] [Related]
18. Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin.
Pessina A; Raimondi A; Croera C; Acchini M; Mineo E; Foti P; Neri MG
Anticancer Drugs; 2001 Jun; 12(5):441-51. PubMed ID: 11395572
[TBL] [Abstract][Full Text] [Related]
19. Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα.
Bergant K; Janežič M; Valjavec K; Sosič I; Pajk S; Štampar M; Žegura B; Gobec S; Filipič M; Perdih A
Eur J Med Chem; 2019 Aug; 175():330-348. PubMed ID: 31096154
[TBL] [Abstract][Full Text] [Related]
20. A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents.
Okoro CO; Fatoki TH
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
